Why the study?
Does monoclonal antibody therapy against T cell subsets improve survival in mice with acute coxsackievirus B3 myocarditis?
Population
Two-week-old male C3H/He mice inoculated with coxsackievirus B3 (CB3)
Comparison
Rat anti-mouse monoclonal antibodies against T… vs Infected controls (untreated)
Design
Preclinical
Follow-up
2 weeks
Authors
Loading...
Does not support clinical use in viral myocarditis; extends preclinical evidence on T-cell targeting and leaves translation open.
Does monoclonal antibody therapy against T cell subsets improve survival in mice with acute coxsackievirus B3 myocarditis?
Combined monoclonal antibody therapy against Lyt 1 and Lyt 2 T cell subsets improves survival and reduces myocardial inflammation in a murine model of coxsackievirus B3 myocarditis.
Kishimoto et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: